Co-Occurring Disorders Editor · Last reviewed January 2025
Understanding the mental health dimensions of benzodiazepine use disorder — how it affects brain chemistry, which mental health conditions most commonly co-occur, and how integrated treatment addresses both — is essential for anyone navigating recovery or supporting someone who is.
How benzodiazepine Affects Mental Health
Benzodiazepines enhance GABA-A receptor function, producing sedation, anxiolysis, and muscle relaxation. Tolerance develops within weeks of regular use, requiring escalating doses to maintain the same effect. Physical dependence develops rapidly. Benzodiazepine withdrawal is medically dangerous — it can cause seizures and delirium similar to alcohol withdrawal — and must be managed with a supervised taper. Abrupt discontinuation after prolonged high-dose use is potentially life-threatening and should never be attempted without medical supervision.
Most Common Co-Occurring Mental Health Conditions
Benzodiazepine use disorders are often iatrogenic — arising from legitimate psychiatric prescriptions for anxiety, insomnia, or PTSD. The conditions most commonly co-occurring with benzodiazepine use disorder are the very conditions for which benzodiazepines are prescribed. This creates a particularly complex clinical situation: the substance being misused was initiated as treatment for the co-occurring mental health condition. The most frequently co-occurring conditions with benzodiazepine use disorder include generalized anxiety disorder, panic disorder, PTSD, insomnia, and depression. These relationships are bidirectional: mental health conditions can drive benzodiazepine use as self-medication, while benzodiazepine use can cause, worsen, or maintain mental health symptoms through direct neurobiological effects and lifestyle disruption.
Diagnostic Challenges
benzodiazepine produces psychiatric symptoms during intoxication and withdrawal that can mimic primary mental health conditions. Careful assessment — ideally after a period of abstinence or stable use — is essential for accurate diagnosis. However, severe psychiatric symptoms that persist well beyond acute intoxication or withdrawal are more likely to reflect a primary co-occurring condition requiring treatment in its own right.
Integrated Treatment
Supervised benzodiazepine tapering — gradually reducing the dose over weeks to months while managing withdrawal symptoms — is the standard approach. The rate of taper must be individualized based on dose, duration of use, substance used, and the patient's response. CBT for anxiety disorders is the most critical concurrent intervention: it addresses the underlying anxiety that drove benzodiazepine use and builds coping skills that reduce the perceived need for anxiolytics during and after the taper. SSRIs/SNRIs, buspirone, and pregabalin offer non-habit-forming alternatives for ongoing anxiety management. Mindfulness-based stress reduction (MBSR) and CBT together have evidence for anxiety reduction that can complement the tapering process.
Getting Help
SAMHSA's National Helpline (1-800-662-4357) provides free, confidential treatment referrals 24/7. The treatment locator at findtreatment.gov allows searching for dual diagnosis programs by location.
Related: Anxiety & Substance Use · Anxiety Disorders Overview · Medication Management